六指魔的个人主页 - 老虎社区

六指魔

六指魔

暂无个人介绍

IP属地：江苏

33关注

0粉丝

0主题

0勋章

2016-08-09

新药三期临床试验结果未达预期

$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#

新药三期临床试验结果未达预期

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":172865062005960,"uuid":"172865062005960","gmtCreate":1463182183455,"gmtModify":1470711071584,"name":"六指魔","pinyin":"lzmliuzhimo","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/80312cf257e1943f848491859e5b65a1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":33,"tweetSize":1,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":27,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"江苏","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":23629,"gmtCreate":1470730676550,"gmtModify":1704872415808,"author":{"id":"172865062005960","authorId":"172865062005960","name":"六指魔","avatar":"https://static.laohu8.com/80312cf257e1943f848491859e5b65a1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"新药三期临床试验结果未达预期","htmlText":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","listText":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","text":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/23629","isVote":1,"tweetType":1,"viewCount":1413,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"112284157742196","authorId":"112284157742196","name":"鼓谜","avatar":"https://static.tigerbbs.com/f08906fb70bff53c4cb0e84ae60cde4b","crmLevel":2,"crmLevelSwitch":0},"content":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌 2016年8月09年, Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存 科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","text":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌 2016年8月09年, Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存 科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","html":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌 2016年8月09年, Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存 科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":23629,"gmtCreate":1470730676550,"gmtModify":1704872415808,"author":{"id":"172865062005960","authorId":"172865062005960","name":"六指魔","avatar":"https://static.laohu8.com/80312cf257e1943f848491859e5b65a1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"新药三期临床试验结果未达预期","htmlText":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","listText":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","text":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/23629","isVote":1,"tweetType":1,"viewCount":1413,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"112284157742196","authorId":"112284157742196","name":"鼓谜","avatar":"https://static.tigerbbs.com/f08906fb70bff53c4cb0e84ae60cde4b","crmLevel":2,"crmLevelSwitch":0},"content":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌 2016年8月09年, Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存 科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","text":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌 2016年8月09年, Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存 科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","html":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌 2016年8月09年, Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存 科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat"}],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}